Skip to main content
Clinical Trials/CTRI/2022/11/047533
CTRI/2022/11/047533
Not yet recruiting
未知

A randomized,single-dose,double-blind,3 way,3-sequence,crossover,study to assess the bioavailabilty of BCO-5 in comparison with unformulated extracts in healthy volunteers.

Akay Natural Ingredients Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Akay Natural Ingredients Pvt Ltd
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Akay Natural Ingredients Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\.BMI between 18\-25 kg/m2 (inclusive)
  • 2\.Females of child bearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening
  • 3\.Subject understands the study procedures, is ready to comply and provide signed informed consent form (ICF) to participate in the study

Exclusion Criteria

  • 1\.Subjects having symptoms of viral infections in the last 2 weeks
  • 2\.Pregnant or lactating women
  • 3\. History of Irritable bowel syndrome, malabsorption or gastrointestinal abnormalities which may affect drug absorption, duodenal ulcer or gastric ulcer, gastritis, Kidney disease, kidney stones, cardiac conditions, Recent blood donation (within 1 month),Current smoker or has quit smoking within last 3months, Alcoholism and/or drug abuse, or heavy drinkers, Immunodeficiency disease (e.g., human immunodeficiency virus infection,Allergy, medication or supplement use that influences the immune system
  • 4\.Subjects with known hypersensitivity to the investigational products.
  • 5\.Subjects who have participated in any clinical trial in the past 1 month.
  • 6\.Any subjects found to have entered in to the study in violation of this protocol or if the subject is uncooperative during the study.
  • 7\.Any other condition that in the opinion of the investigator that does not justify the subjectâ??s participation in the trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A single dose three-way crossover oral bioavailability study of ß-alanine capsules in comparison with conventional ß-alanine in healthy human volunteers in fasting conditions
CTRI/2024/03/063457atural Alternatives International
Recruiting
Not Applicable
A randomized, double-blind, single-dose, 3-way, parallel group, comparator-controlled, adaptive design, pharmacokinetic, safety, and tolerability study in healthy male volunteers to evaluate bioequivalence of CBT124 to Avastin(Registered Trademark) (EU and US)non-squamous non-small cell lung cancermetastatic colorectal cancerCancer - Lung - Non small cellCancer - Bowel - Back passage (rectum) or large bowel (colon)
ACTRN12616000428460Cipla BioTec Pvt. Ltd.150
Not yet recruiting
Phase 1
A study comparing the study drug BP02 and Herceptin® in healthy men.HER2 Positive TumoursCancer - Any cancer
ACTRN12621000573853CuraTeQ Biologics Private Limited111
Not yet recruiting
Phase 1
A bioequivalence study of a bevacizumab biosimilar in healthy male subjects
CTRI/2019/02/017428Intas Pharmaceuticals Limited
Active, not recruiting
Phase 1
A phase 3 clinical study to study the effects of different doses of phenylephrine hydrochloride in combination with paracetamol and/or ibuprofen, in people with blocked nose due to the common cold.nasal congestionMedDRA version: 18.0Level: PTClassification code 10028735Term: Nasal congestionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
EUCTR2015-002385-23-GBAFT Pharmaceuticals Ltd275